Amarin (AMRN) Stock Price, News & Analysis

Company Overview

Amarin Corporation plc is a biotechnology company specializing in the development and commercialization of therapeutics for cardiovascular health. Headquartered in Dublin, Ireland, with a U.S. operational hub in Bridgewater, New Jersey, Amarin focuses primarily on novel therapies to address unmet needs in cardiometabolic diseases. The company’s core research and development efforts center on lipid science and inflammation, with an emphasis on harnessing the therapeutic potential of omega-3 fatty acids.

The company’s flagship product, Vascepa (icosapent ethyl), is an EPA-only prescription therapy approved in the United States to reduce cardiovascular risk in certain patient populations with elevated triglyceride levels. Vascepa has been the subject of large‐scale clinical trials, demonstrating its ability to lower residual cardiovascular risk when added to statin therapy. Amarin has also secured regulatory approvals for Vazkepa, a formulation of icosapent ethyl, in select European markets, marking an important step in its international commercialization strategy.

Founded in 1993, Amarin has grown from a small research enterprise into a globally focused biopharmaceutical company. The company completed its initial public offering on the NASDAQ in 2004 under the ticker AMRN. Since 2013, John F. Thero has served as Chief Executive Officer, guiding Amarin through pivotal regulatory milestones and expanding its commercial presence. Under Thero’s leadership, the company has forged strategic partnerships and optimized its manufacturing capabilities to support sustained product supply.

Beyond its lead product, Amarin pursues ongoing studies to explore additional indications for icosapent ethyl and to evaluate novel formulations aimed at improving patient adherence and outcomes. The company’s multidisciplinary team of scientists, clinicians and regulatory experts works across its U.S. and European sites to advance its pipeline. Through continued clinical research, strategic collaborations and a commitment to cardiovascular innovation, Amarin strives to enhance long‐term health prospects for patients worldwide.

Key Stats

• Today's Range: $15.89 to $16.95
• 50-Day Range: $10.15 to $17.33
• 52-Week Range: $7.08 to $17.49
• Volume: 130,426 shs
• Average Volume: 83,411 shs
• Market Capitalization: $330.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Sell

Amarin Stock Analysis - MarketRank™

Amarin scored higher than 9% of companies evaluated by MarketBeat, and ranked 911th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Amarin has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Amarin has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Amarin are expected to decrease in the coming year, from ($0.15) to ($0.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amarin is -4.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amarin is -4.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Amarin has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.17% of the float of Amarin has been sold short.

Short Interest Ratio / Days to Cover

Amarin has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Amarin has recently increased by 4.23%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amarin does not currently pay a dividend.

Dividend Growth

Amarin does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.17% of the float of Amarin has been sold short.

Short Interest Ratio / Days to Cover

Amarin has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Amarin has recently increased by 4.23%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.34

News Sentiment

Amarin has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Amarin this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for AMRN on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Amarin to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Amarin insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.96% of the stock of Amarin is held by insiders.

Percentage Held by Institutions

Only 22.25% of the stock of Amarin is held by institutions.

AMRN Stock Analysis - Frequently Asked Questions

How have AMRN shares performed this year?

Amarin's stock was trading at $9.70 at the beginning of the year. Since then, AMRN shares have increased by 64.7% and is now trading at $15.98.

How were Amarin's earnings last quarter?

Amarin Corporation PLC (NASDAQ:AMRN) issued its quarterly earnings results on Wednesday, May, 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.02. Amarin had a negative net margin of 41.07% and a negative trailing twelve-month return on equity of 17.21%.
Read the conference call transcript.

When did Amarin's stock split?

Amarin's stock reverse split on Friday, April 11th 2025.The 1-20 reverse split was announced on Wednesday, March 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Does Amarin have any subsidiaries?

Amarin subsidiaries include Ester Neurosciences, Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc., Amarin Switzerland GmbH, Amarin UK Limited, and Ester Neurosciences Limited.

Who are Amarin's major shareholders?

Top institutional investors of Amarin include LCM Capital Management Inc (0.21%). Insiders that own company stock include Aaron Berg, Steven B Ketchum and Patrick Holt.
View institutional ownership trends.

How do I buy shares of Amarin?

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amarin investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AMRN
• CIK: 897448
• Web: www.amarincorp.com
• Phone: (531) 669-9020
• Fax: N/A
• Employees: 360
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Amarin: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: -26.2%
• Consensus Rating: Sell
• Rating Score (0-4): 1.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$82.18 million
• Net Margins: -41.07%
• Pretax Margin: -38.38%
• Return on Equity: -17.21%
• Return on Assets: -12.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.53
• Quick Ratio: 2.55

Sales & Book Value

• Annual Sales: $228.61 million
• Price / Sales: 1.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $23.62 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 20,710,000
• Free Float: 20,301,000
• Market Cap: $336.54 million
• Optionable: Optionable
• Beta: 0.82